Literal source text
Lobbying issues and bill citations
HCR · Health Issues
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
Literal federal measure citations: HR 1518
PHA · Pharmacy
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
Literal federal measure citations: HR 946, S. 1862, H.R.1
MED · Medical/Disease Research/Clinical Labs
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
Literal federal measure citations: HR 1262, S 932, H.R.1, HR 4709, H.R. 9102
MMM · Medicare/Medicaid
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
Literal federal measure citations: H.R.1, H.R. 9509
CPT · Copyright/Patent/Trademark
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
Literal federal measure citations: S.1040, S. 2658
TAX · Taxation/Internal Revenue Code
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
Literal federal measure citations: H.R. 1414, H.R.1